Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 906-083-8 | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Developmental toxicity / teratogenicity
Administrative data
- Endpoint:
- developmental toxicity
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: guideline study acc. to GLP
Cross-reference
- Reason / purpose for cross-reference:
- reference to same study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 010
- Report date:
- 2010
Materials and methods
Test guidelineopen allclose all
- Qualifier:
- according to guideline
- Guideline:
- other: OECD Guideline 421
- Deviations:
- yes
- Remarks:
- dermal application
- Qualifier:
- according to guideline
- Guideline:
- other: EPA OPPTS 870.3550
- GLP compliance:
- yes (incl. QA statement)
- Limit test:
- yes
Test material
- Reference substance name:
- Geraniol
- EC Number:
- 203-377-1
- EC Name:
- Geraniol
- Cas Number:
- 106-24-1
- Molecular formula:
- C10H18O
- IUPAC Name:
- 3,7-dimethylocta-(E)-2,6-dien-1-ol
- Details on test material:
- liquid, colorless, clear
Constituent 1
Test animals
- Species:
- rat
- Strain:
- Wistar
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River Laboratories, Research Models and Services GmbH, Germany
- Age at study initiation: 11-12 weeks
- Housing: Makrolon cage type M III
- No. of animals per cage: 1 animal,
- Exceptions: during mating: 1 male/ 1 female per cage; during rearing up to PND4: 1 dam with her litter
- Enrichment: Wooden gnawing blocks (Type NGM E-022)
- Bedding: Type Lignocel PS 14 fibres, dustfree bedding
- Diet: Ground Kliba maintenance diet mouse/rat "GLP"; ad libitum
- Water: ad libitum
- Acclimation period: 7 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 20-24
- Humidity (%): 30-70
- Air changes (per hr): 15
- Photoperiod (hrs dark / hrs light): 12:12
Administration / exposure
- Route of administration:
- dermal
- Vehicle:
- corn oil
- Details on exposure:
- - Preparation frequency: The preparations was prepared at intervals for which the stability is guaranteed (7 days).
- Application area: Intact clipped skin of the back (dorsal and dorsolateral areas of the trunk; not less than 10% of the body surface); the first clipping was carried out at least 24 hours before the randomization. The rats were reclipped at least once a week (depending on the hair growth).
- Type of application: Dermal application of the test-substance preparations to the clipped intact dorsal skin by means was carried out with 3-mL syringes (3CC Syringe, supplied by Becton, Dickinson & Co., Franklin Lakes, U.S.A.) and a semiocclusive dressing (4 layers of absorbent gauze1) and stretch bandage2)). The test-substance preparation was applied to the dorsal skin with the syringe in each case. After removal of the dressing, the application area was washed with lukewarm water.
- Volume to be applied: 4 mL/kg body weight (related to the body weight determined most recently in each case) - Details on mating procedure:
- - M/F ratio per cage: 1:1
- Length of cohabitation: up tp 14 days
- Proof of pregnancy: sperm in vaginal smear referred to as day 0 of pregnancy - Duration of treatment / exposure:
- Application period:
Males: From day 0 (start of administration period) until sacrifice
Females: From day 0 (start of administration period) until GD 19 - Frequency of treatment:
- daily for at least 6 hours
Doses / concentrationsopen allclose all
- Remarks:
- Doses / Concentrations:
450 mg/kg bw/day
Basis:
nominal conc.
initial high dose
- Remarks:
- Doses / Concentrations:
300 mg/kg bw/day
Basis:
nominal conc.
reduced high dose due to massive skin irritation after 10 days of application
- Remarks:
- Doses / Concentrations:
150 mg/kg bw/day
Basis:
nominal conc.
mid dose
- Remarks:
- Doses / Concentrations:
50 mg/kg bw/day
Basis:
nominal conc.
low dose
- No. of animals per sex per dose:
- 10
- Control animals:
- yes, concurrent vehicle
Examinations
- Maternal examinations:
- CAGE SIDE OBSERVATIONS: Yes
A check for moribund and dead animals was made twice daily on working days and once daily on Saturdays, Sundays and public holidays. If animals were in a moribund state, they were sacrificed and necropsied.
DETAILED CLINICAL OBSERVATIONS: Yes
A cageside examination was conducted at least once daily for any signs of morbidity, pertinent behavioral changes and signs of overt toxicity. Abnormalities and changes were documented for each animal.
The parturition and lactation behavior of the dams was generally evaluated in the morning in combination with the daily clinical inspection of the dams. Only particular findings (e.g. disability to deliver or umbilical cord not cut) were documented on an individual dam basis.
On weekdays (except public holidays) the parturition behavior of the dams was inspected in the afternoons in addition to the evaluations in the mornings.
The day of parturition was considered to be the 24-hour period from about 15:00 h of one day until about 15:00 h of the following day. Deviations from this procedure were on Saturdays, Sundays and public holidays.
BODY WEIGHT:
In general, the body weight of the male and female parental animals was determined once a week at the same time of the day (in the morning).
The body weight change of the animals was calculated from these results.
The following exceptions are notable for the female parental animals:
• During the mating period, the females were weighed on the day of positive evidence of sperm (GD 0) and on GD 7, 14 and 20.
• Females showing no positive evidence of sperm in the vaginal smear were weighed once a week during this mating interval as were the males.
• Females with litter were weighed on the day of parturition (PND 0) and on PND 4.
• Females without litter were weighed once a week.
• Females between PND 4 and sacrifice were weighed once a week.
FOOD CONSUMPTION:
Generally, food consumption was determined once a week (in a period of 7 days) for male and female parental animals, with the following exceptions:
• Food consumption was not determined after the 2nd premating week (male parental animals) and during the mating period (male and female parental animals).
• Food consumption of the females with evidence of sperm was determined for GD 0-7, 7-14 and 14-20.
• Food consumption of the females, which gave birth to a litter, was determined for PND 1-4.
Food consumption was not determined in the females without positive evidence of sperm during mating and gestation periods and in the females without litter during lactation period. - Ovaries and uterine content:
- After sacrifice of the female animals the uterus and ovaries were removed and the implantation sites were counted. To determine the number of implantation sites in apparently non-pregnant animals, the uteri from those females were stained in 10% ammonium sulfide solution for about 5 minutes according to the method of SALEWSKI (Salewski, E.; 1964). Then, the respective uteri were rinsed carefully with fresh tap water. The implantation sites
were recorded for the calculation of the postimplantation loss. - Fetal examinations:
- Pup number and status at delivery
All pups delivered from the F0 parents were examined as soon as possible on the day of birth to determine the total number of pups and the number of liveborn and stillborn pups in each litter. At the same time, the pups were examined for gross-morphological changes. Pups, which died before the first determination of their status on the day of birth, were defined as stillborn pups.
Pup viability/ mortality
In general, a check was made for any dead or moribund pups twice daily on workdays (once in the morning and once in the afternoon) or as a rule, only in the morning on Saturdays, Sundays or public holidays.
The number and percentage of dead pups on the day of birth (PND 0) and pups dying during the lactation period were determined. However, pups which died accidentally and pups which were sacrificed due to maternal death were not included in these calculations. The number of live pups/litter was calculated on the day of birth and on PND 4. Furthermore, the viability index was calculated according to the following formula:
Viability index (%) = (number of live pups on day 4 after birth/number of liveborn pups on the day of birth)x 100
Sex ratio
On the day of birth (PND 0) the sex of the pups was determined by observing the distance between the anus and the base of the genital tubercle. Normally, the anogenital distance is considerably greater in male than in female pups. The sex of the pups finally confirmed at necropsy.
The sex ratio was calculated at PND 0 and 4 according to the following formula:
Sex ratio = (number of live male or female pups on day 0/4 / number of live male and female pups on day 0/4)x100
Pup clinical observations
The live pups were examined daily for clinical symptoms (including gross-morphological findings) during the clinical inspection of the dams. If pups showed particular findings, these were documented with the dam concerned.
Pup body weight data
The pups were weighed one day after birth (PND 1) and on PND 4. Pups' body weight change was calculated from these results.
Furthermore the body weights on PND 1 were used for the calculation of "runts" (pups, which weighed less than 25% of the mean weight of the respective control pups). The individual weights were always determined at about the same time of the day (in the morning).
In the relevant summary tables pup body weights (including "runts") and pup body weight gains are listed for males, females as well as males and females together.
Pup necropsy observations
All surviving pups (sacrificed on PND 4 under isoflurane anesthesia with CO2), all stillborn pups and those pups, which died ahead of schedule, were examined externally, eviscerated and their organs were assessed macroscopically.
All pups without any notable findings or abnormalities were discarded after their macroscopic evaluation.
Results and discussion
Results: maternal animals
Maternal developmental toxicity
- Details on maternal toxic effects:
- Maternal toxic effects:yes. Remark: massive skin irritation at 450 mg/kg bw/day
Details on maternal toxic effects:
Clinical observations for males
For males, several dermal findings were noted in test groups 3 (450 and 300 mg/kg bw/d). Starting on study day 10, 5 rats showed focal and multifocal red spots on treated skin on several days. Starting on study day 11, 9 male rats showed focal scales on treated skin on several days. One rat showed focal erosion on treated skin on several days beginning on study day 14. Starting on study day 15, 5 rats showed slight erythema on treated skin onseveral days.
Similar findings but less pronounced were observed in male animals of test group 2 (150 mg/kg bw/d), i.e. focal red spots on treated skin on several days in 5 animals from study day 9 onwards, focal scales on treated skin starting on study day 13 in 2 animals and slight erythema on treated skin in 3 animals starting on study day 15.
No treatment-related findings were observed in male animals of test group 1 (50 mg/kg bw/d).
Clinical observations for females
As observed for the male animals of test group 3 (450 and 300 mg/kg bw/d) different dermal findings on treated skin were noted on several days, i.e. during premating, mating and lactation periods. Starting on study day 3, seven animals showed slight and moderate erythema on several days of the study. In addition, some animals of test group 3 (450 and 300 mg/kg bw/d) showed multifocal, focal and diffuse scales on treated skin starting on study day 5.
Similar findings but less pronounced were observed in female animals of test group 2 (150 mg/kg bw/d), i.e. focal red spots, slight erythema and focal scales on treated skin on several days of the study.
In test group 1 (50 mg/kg bw/d) slight erythema as well as focal and diffuse scales on treated skin were observed in individual animals at different time points.
One female of test group 3 (450 and 300 mg/kg bw/d), which did not deliver pups, showed a vaginal hemorrhage 27 days after mating.
In one female animal of test group 2 (150 mg/kg bw/d) a severe thoracal injury was observed during premating. It was a self inflicted injury which was caused by the animal’s attempt to get rid off the gauze. The injury became more severe by time and the animal had to be sacrificed in a moribund state in study week 1. A red-brown lesion was noted on the thorax of this animal, which correlated to an erosion/ulcer on the skin.
Histopathology
Lymphocytic infiltrates were observed in treated skin sections which were distributed in an interface pattern (10/10 males and 5/10 females at 450 mg/kg bw/d [test group 3] graded minimal to slight, 7/10 males at 150 mg/kg bw/d [test group 2] graded minimal, 2/10 males at 50 mg/kg bw/d [test group 1] graded minimal). All other findings noted were single observations which were considered to be incidental and spontaneous in origin and without any relation to treatment.
Effect levels (maternal animals)
- Dose descriptor:
- NOAEL
- Effect level:
- 300 mg/kg bw/day (actual dose received)
- Basis for effect level:
- other: maternal toxicity
Results (fetuses)
- Details on embryotoxic / teratogenic effects:
- Embryotoxic / teratogenic effects:no effects
Details on embryotoxic / teratogenic effects:
Pup number and status at delivery
The mean number of delivered pups per dam and the rate of liveborn and stillborn pups were evenly distributed among test group 0, 1, 2 and 3 (0, 50, 150 and 450 and 300 mg/kg bw/d). The respective values reflect the normal range of biological variation inherent in the strain used in this study.
Pup viability/mortality
No significant findings for pups that died during lactation were observed. The viability index as indicator for pup mortality between PND 0-4 varied between 99% (test group 1, 50 mg/kg bw/d and test group 3, 450 and 300 mg/kg bw/d) and 100% (test group 0, 0 mg/kg bw/d and test group 2, 150 mg/kg bw/d). No test substance-related changes were obtained.
One male pup delivered by one dam of test group 1 (50 mg/kg bw/d) was sacrificed moribund on PND 0 as it showed malformation of the skull, anophthalmia and cleft lip (see Pup clinical observations).
Sex ratio
The sex distribution and sex ratios of live F1 pups on the day of birth and PND 4 did not show biologically relevant differences between the control and test groups 1-3.
Pup clinical observations
One dam of test group 1 (50 mg/kg bw/d) gave birth to a male pup with a deformation of its snout. On first sight a cleft lip and anophthalmia were seen. The staining of the pups skull showed that several bones (e.g. basisphenoid, palatine, incisive, nasal incl. cartilage and maxilla) were deformed and/or displaced.
Therefore, F1 pups did not show adverse clinical signs up to scheduled sacrifice on PND 4.
Pup body weight data
The mean body weight of female pups in test group 3 (450 and 300 mg/kg bw/d) was increased 11% on PND 1.
Pup body weight changes in the test substance-treated groups 1-3 (50, 150 and 450 and 300 mg/kg bw/d) were comparable to the concurrent control values.
The numbers of runts were 1 female in the control group and 1 male in test group 3 (450 and 300 mg/kg bw/d) on PND 1. Since a dose-response relationship was not observed a relation to dosing was not assumed.
Pup necropsy observations
During the necropsy of all F1 pups no test substance-related findings were observed.
Effect levels (fetuses)
- Dose descriptor:
- NOAEL
- Effect level:
- 300 mg/kg bw/day (actual dose received)
- Basis for effect level:
- other: fetotoxicity
Fetal abnormalities
- Abnormalities:
- not specified
Overall developmental toxicity
- Developmental effects observed:
- not specified
Applicant's summary and conclusion
- Conclusions:
- The dermal administration of Geraniol Extra revealed only local signs of toxicity in male and female Wistar rats at all dose levels. This finding was related to the irritating potential of the test substance. No adverse findings were observed for developmental toxicity in any of the tested groups.
Thus, concerning toxicity to reproduction the test substance does not need to be classified neither according to Dir 1999/45/EC nor to Reg (EC) 1272/2008. - Executive summary:
Geraniol Extra was administered via dermal administration to groups of 10 male and 10 female Wistar rats (F0 animals) at dose levels of 0 (vehicle control; test group 0), 50 (test group 1), 150 (test group 2) and 450 mg/kg bw/d (test group 3) in order to observe the possible effects of the test substance on the integrity and performance of the reproductive system in both sexes. Due to severe dermal findings, the dose level for test group 3 was decreased to 300 mg/kg bw/d from study day 10 onwards.
Regarding clinical examinations, only signs of local dermal toxicity were observed for males and females at all dose levels. No changes in food consumption and body weight data were seen at any dose level.
Fertility indices for male and female animals were not impaired by test-substance administration.
Regarding pathology, there were no treatment-related necropsy or histological findings in ovaries, testes or epididymides associated with dermal administration of the test substance. The local minimal inflammatory reactions in the skin of treated males (test groups 1-3) and females (test group 3 only) were regarded as related to treatment and adverse.
No adverse findings were observed for developmental toxicity in any of the tested groups.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.